STOCK TITAN

[8-K] Seacoast Banking Corp of Florida Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Jaguar Health (JAGX) has filed a Form S-3 to register up to 1,409,732 common shares for resale by existing investors. The stock derives from (i) 481,150 shares underlying 6 % convertible Replacement Notes issued 24 Jun 2025 (conversion price $5.535–$5.555, maturity 30 Jan 2026) and (ii) 928,582 shares issuable on cash or cash-less exercise of accompanying warrants (exercise price $2.70, 18-month term). At the 23 Jul 2025 close of $2.38 the warrant strikes sit 13 % above market while the note conversion price is >130 % above market. If fully converted/exercised the new shares would expand the current 1.914 million share float by roughly 74 %, creating a sizeable overhang.

The company will not receive proceeds from secondary sales; only a full cash exercise of all warrants could raise ~$2.5 million, earmarked for working capital. The filing follows several recent financings (March convertible notes and May registered direct offering) and occurs alongside an active GI-focused drug pipeline led by crofelemer (FDA-approved Mytesi, multiple Phase 2/3 programs, orphan designations) and the October 2024 U.S. launch of Gelclair for oral mucositis. While pipeline breadth offers optionality, near-term investors must weigh dilution risk and potential price pressure from selling stockholders against the modest capital infusion possible from warrant exercises.

Jaguar Health (JAGX) ha depositato un modulo S-3 per registrare fino a 1.409.732 azioni ordinarie da rivendere da parte degli investitori esistenti. Le azioni derivano da (i) 481.150 azioni sottostanti a note convertibili sostitutive al 6% emesse il 24 giugno 2025 (prezzo di conversione $5,535–$5,555, scadenza 30 gennaio 2026) e (ii) 928.582 azioni emettibili tramite esercizio in contanti o senza contanti dei warrant allegati (prezzo di esercizio $2,70, durata 18 mesi). Al prezzo di chiusura del 23 luglio 2025 di $2,38, il prezzo di esercizio dei warrant è circa il 13% superiore al mercato, mentre il prezzo di conversione delle note è oltre il 130% superiore al mercato. Se completamente convertite/esercitate, le nuove azioni aumenterebbero il flottante attuale di 1,914 milioni di azioni di circa il 74%, creando una significativa pressione di vendita.

L'azienda non riceverà proventi dalle vendite secondarie; solo un esercizio in contanti completo di tutti i warrant potrebbe raccogliere circa $2,5 milioni, destinati al capitale circolante. Il deposito segue diverse recenti operazioni di finanziamento (note convertibili di marzo e offerta diretta registrata di maggio) e avviene parallelamente a un portafoglio farmaceutico focalizzato sul tratto gastrointestinale guidato da crofelemer (Mytesi approvato dalla FDA, diversi programmi di fase 2/3, designazioni per farmaci orfani) e al lancio negli Stati Uniti di Gelclair per la mucosite orale previsto per ottobre 2024. Sebbene l'ampiezza del portafoglio offra opzioni, gli investitori a breve termine devono valutare il rischio di diluizione e la potenziale pressione sul prezzo derivante dalla vendita di azioni rispetto al modesto apporto di capitale possibile dall'esercizio dei warrant.

Jaguar Health (JAGX) ha presentado un Formulario S-3 para registrar hasta 1.409.732 acciones ordinarias para reventa por parte de inversores existentes. Las acciones provienen de (i) 481.150 acciones subyacentes a Notas Convertibles de Reemplazo al 6% emitidas el 24 de junio de 2025 (precio de conversión $5.535–$5.555, vencimiento 30 de enero de 2026) y (ii) 928.582 acciones emitibles mediante el ejercicio en efectivo o sin efectivo de los warrants adjuntos (precio de ejercicio $2,70, plazo de 18 meses). Al cierre del 23 de julio de 2025 en $2,38, el precio de ejercicio de los warrants está un 13% por encima del mercado, mientras que el precio de conversión de las notas supera el 130% del mercado. Si se convierten/ejercitan completamente, las nuevas acciones ampliarían el flotante actual de 1,914 millones de acciones en aproximadamente un 74%, creando una considerable sobreoferta.

La compañía no recibirá ingresos por ventas secundarias; solo un ejercicio en efectivo completo de todos los warrants podría recaudar aproximadamente $2,5 millones, destinados a capital de trabajo. La presentación sigue a varias financiaciones recientes (notas convertibles de marzo y oferta directa registrada en mayo) y ocurre junto a una cartera activa de medicamentos centrados en el tracto gastrointestinal liderada por crofelemer (Mytesi aprobado por la FDA, múltiples programas de fase 2/3, designaciones huérfanas) y el lanzamiento en EE.UU. de Gelclair para mucositis oral previsto para octubre de 2024. Aunque la amplitud de la cartera ofrece opciones, los inversores a corto plazo deben sopesar el riesgo de dilución y la posible presión sobre el precio por parte de los accionistas vendedores frente a la modesta inyección de capital posible mediante el ejercicio de los warrants.

Jaguar Health (JAGX)는 기존 투자자들이 재판매할 수 있도록 최대 1,409,732주의 보통주를 등록하기 위해 Form S-3를 제출했습니다. 해당 주식은 (i) 2025년 6월 24일 발행된 6% 전환 대체 채권에 기초한 481,150주(전환 가격 $5.535–$5.555, 만기 2026년 1월 30일)와 (ii) 부속 워런트의 현금 또는 무현금 행사로 발행 가능한 928,582주(행사가격 $2.70, 18개월 기간)에서 유래합니다. 2025년 7월 23일 종가 $2.38 기준으로 워런트 행사가격은 시장가보다 약 13% 높으며, 채권 전환 가격은 시장가보다 130% 이상 높습니다. 완전 전환/행사 시 신규 주식은 현재 191만 4천주의 유통 주식 수를 약 74% 확대하여 상당한 매도 압력을 초래할 수 있습니다.

회사는 2차 판매로부터 수익을 받지 않습니다; 모든 워런트를 현금으로 완전히 행사할 경우 약 $250만의 자금을 조달할 수 있으며, 이는 운전자본으로 사용될 예정입니다. 이번 제출은 최근 몇 차례의 자금 조달(3월 전환사채 및 5월 등록 직접 공모)에 이어 이루어졌으며, FDA 승인된 Mytesi를 포함한 크로펠레머 주도 하에 여러 2/3상 임상 프로그램과 희귀의약품 지정이 진행 중인 위장관(GI) 중심의 활발한 신약 파이프라인과 2024년 10월 미국에서 구강 점막염 치료제 Gelclair 출시와 함께 진행되고 있습니다. 파이프라인의 폭넓은 선택권이 있지만, 단기 투자자들은 희석 위험과 매도 주주들의 주식 매도로 인한 가격 압력 가능성을 워런트 행사로 인한 소규모 자금 조달과 비교하여 신중히 고려해야 합니다.

Jaguar Health (JAGX) a déposé un formulaire S-3 pour enregistrer jusqu'à 1 409 732 actions ordinaires en revente par des investisseurs existants. Les actions proviennent de (i) 481 150 actions sous-jacentes à des billets convertibles de remplacement à 6 % émis le 24 juin 2025 (prix de conversion $5,535–$5,555, échéance 30 janvier 2026) et (ii) 928 582 actions pouvant être émises lors de l'exercice en numéraire ou sans numéraire des bons de souscription associés (prix d'exercice $2,70, durée de 18 mois). À la clôture du 23 juillet 2025 à $2,38, les prix d'exercice des bons sont environ 13 % au-dessus du marché tandis que le prix de conversion des billets est supérieur de plus de 130 % au marché. En cas de conversion/exercice complet, les nouvelles actions augmenteraient le flottant actuel de 1,914 million d'actions d'environ 74 %, créant un important surplomb.

La société ne recevra pas de produit des ventes secondaires ; seul un exercice intégral en numéraire de tous les bons pourrait lever environ 2,5 millions de dollars, destinés au fonds de roulement. Ce dépôt fait suite à plusieurs financements récents (billets convertibles de mars et offre directe enregistrée de mai) et intervient parallèlement à un pipeline actif de médicaments axés sur le système gastro-intestinal, mené par le crofelemer (Mytesi approuvé par la FDA, plusieurs programmes de phases 2/3, désignations orphelines) et au lancement prévu en octobre 2024 aux États-Unis de Gelclair pour la mucite buccale. Bien que l'étendue du pipeline offre des options, les investisseurs à court terme doivent peser le risque de dilution et la pression potentielle sur le prix liée aux actionnaires vendeurs par rapport à la modeste injection de capital possible via l'exercice des bons.

Jaguar Health (JAGX) hat ein Formular S-3 eingereicht, um bis zu 1.409.732 Stammaktien zum Wiederverkauf durch bestehende Investoren zu registrieren. Die Aktien stammen aus (i) 481.150 Aktien, die zugrunde liegenden 6 % konvertiblen Ersatzanleihen vom 24. Juni 2025 (Umwandlungspreis $5,535–$5,555, Fälligkeit 30. Januar 2026) und (ii) 928.582 Aktien, die durch Barausübung oder Bar-freie Ausübung der begleitenden Warrants ausgegeben werden können (Ausübungspreis $2,70, Laufzeit 18 Monate). Beim Schlusskurs vom 23. Juli 2025 von $2,38 liegen die Warrant-Ausübungspreise etwa 13 % über dem Markt, während der Umwandlungspreis der Anleihen mehr als 130 % über dem Markt liegt. Bei vollständiger Umwandlung/Ausübung würden die neuen Aktien den aktuellen Streubesitz von 1,914 Millionen Aktien um etwa 74 % erhöhen und damit einen erheblichen Überhang schaffen.

Das Unternehmen erhält keine Erlöse aus Sekundärverkäufen; nur eine vollständige Barausübung aller Warrants könnte etwa 2,5 Millionen US-Dollar einbringen, die für das Betriebskapital vorgesehen sind. Die Einreichung folgt mehreren jüngsten Finanzierungen (März konvertible Anleihen und Mai registriertes Direktangebot) und erfolgt parallel zu einer aktiven, auf den Magen-Darm-Trakt fokussierten Medikamentenpipeline, angeführt von Crofelemer (FDA-zugelassenes Mytesi, mehrere Phase-2/3-Programme, Orphan-Designationen) sowie der Markteinführung von Gelclair gegen orale Mukositis in den USA im Oktober 2024. Obwohl die Breite der Pipeline Optionen bietet, müssen kurzfristige Investoren das Verwässerungsrisiko und den möglichen Preisdruck durch verkaufende Aktionäre gegen den bescheidenen Kapitalzufluss aus der Ausübung der Warrants abwägen.

Positive
  • Potential $2.5 million in cash proceeds if all $2.70 warrants are exercised.
  • Note conversion price ($5.535–$5.555) is well above current market, reducing likelihood of immediate conversion-driven selling.
  • Filing enhances liquidity for existing holders and removes Rule 144 timing uncertainty.
Negative
  • Registration adds 1.41 million shares, a ~74 % potential increase in float, leading to dilution risk.
  • Warrants priced near market could generate sell pressure once shares are free trading.
  • Company receives no cash from secondary share sales, limiting near-term balance-sheet improvement.
  • Continued use of convertible debt and warrant structures signals ongoing capital needs.

Insights

TL;DR: Filing registers 1.41 M resale shares—74 % dilution, limited cash to JAGX; sizeable supply overhang outweighs modest ~$2.5 M warrant proceeds.

The S-3 enables holders of June 2025 Replacement Notes and warrants to freely trade 1.41 M shares, versus only 1.91 M currently outstanding. Although note conversion is struck far above market, the $2.70 warrants sit close to spot, making exercise and immediate resale plausible. Because proceeds flow to the company only on cash exercise—and total just ~$2.5 M—the balance of risks skews negative: material dilution, potential downward pressure as insiders and funds monetize positions, and continued dependence on external capital to advance trials. Investors should monitor selling volume and the company’s cash runway, which was not disclosed here.

TL;DR: Registration clears cap-table clutter; pipeline still hinges on crofelemer progress and orphan strategies.

From an operational view, Jaguar retains full global rights to crofelemer and is pursuing multiple niche indications—SBS, MVID, CTD—supported by orphan incentives and proof-of-concept data. The filing itself is routine for financing housekeeping, but it underscores ongoing reliance on convertible structures rather than strategic partners. With warrants just above market the company could access quick, low-cost capital, yet that option dilutes shareholders without guaranteeing clinical inflection points. Milestones such as FDA Type C feedback on breast-cancer diarrhea prophylaxis and early-access EU programs remain primary value drivers.

Jaguar Health (JAGX) ha depositato un modulo S-3 per registrare fino a 1.409.732 azioni ordinarie da rivendere da parte degli investitori esistenti. Le azioni derivano da (i) 481.150 azioni sottostanti a note convertibili sostitutive al 6% emesse il 24 giugno 2025 (prezzo di conversione $5,535–$5,555, scadenza 30 gennaio 2026) e (ii) 928.582 azioni emettibili tramite esercizio in contanti o senza contanti dei warrant allegati (prezzo di esercizio $2,70, durata 18 mesi). Al prezzo di chiusura del 23 luglio 2025 di $2,38, il prezzo di esercizio dei warrant è circa il 13% superiore al mercato, mentre il prezzo di conversione delle note è oltre il 130% superiore al mercato. Se completamente convertite/esercitate, le nuove azioni aumenterebbero il flottante attuale di 1,914 milioni di azioni di circa il 74%, creando una significativa pressione di vendita.

L'azienda non riceverà proventi dalle vendite secondarie; solo un esercizio in contanti completo di tutti i warrant potrebbe raccogliere circa $2,5 milioni, destinati al capitale circolante. Il deposito segue diverse recenti operazioni di finanziamento (note convertibili di marzo e offerta diretta registrata di maggio) e avviene parallelamente a un portafoglio farmaceutico focalizzato sul tratto gastrointestinale guidato da crofelemer (Mytesi approvato dalla FDA, diversi programmi di fase 2/3, designazioni per farmaci orfani) e al lancio negli Stati Uniti di Gelclair per la mucosite orale previsto per ottobre 2024. Sebbene l'ampiezza del portafoglio offra opzioni, gli investitori a breve termine devono valutare il rischio di diluizione e la potenziale pressione sul prezzo derivante dalla vendita di azioni rispetto al modesto apporto di capitale possibile dall'esercizio dei warrant.

Jaguar Health (JAGX) ha presentado un Formulario S-3 para registrar hasta 1.409.732 acciones ordinarias para reventa por parte de inversores existentes. Las acciones provienen de (i) 481.150 acciones subyacentes a Notas Convertibles de Reemplazo al 6% emitidas el 24 de junio de 2025 (precio de conversión $5.535–$5.555, vencimiento 30 de enero de 2026) y (ii) 928.582 acciones emitibles mediante el ejercicio en efectivo o sin efectivo de los warrants adjuntos (precio de ejercicio $2,70, plazo de 18 meses). Al cierre del 23 de julio de 2025 en $2,38, el precio de ejercicio de los warrants está un 13% por encima del mercado, mientras que el precio de conversión de las notas supera el 130% del mercado. Si se convierten/ejercitan completamente, las nuevas acciones ampliarían el flotante actual de 1,914 millones de acciones en aproximadamente un 74%, creando una considerable sobreoferta.

La compañía no recibirá ingresos por ventas secundarias; solo un ejercicio en efectivo completo de todos los warrants podría recaudar aproximadamente $2,5 millones, destinados a capital de trabajo. La presentación sigue a varias financiaciones recientes (notas convertibles de marzo y oferta directa registrada en mayo) y ocurre junto a una cartera activa de medicamentos centrados en el tracto gastrointestinal liderada por crofelemer (Mytesi aprobado por la FDA, múltiples programas de fase 2/3, designaciones huérfanas) y el lanzamiento en EE.UU. de Gelclair para mucositis oral previsto para octubre de 2024. Aunque la amplitud de la cartera ofrece opciones, los inversores a corto plazo deben sopesar el riesgo de dilución y la posible presión sobre el precio por parte de los accionistas vendedores frente a la modesta inyección de capital posible mediante el ejercicio de los warrants.

Jaguar Health (JAGX)는 기존 투자자들이 재판매할 수 있도록 최대 1,409,732주의 보통주를 등록하기 위해 Form S-3를 제출했습니다. 해당 주식은 (i) 2025년 6월 24일 발행된 6% 전환 대체 채권에 기초한 481,150주(전환 가격 $5.535–$5.555, 만기 2026년 1월 30일)와 (ii) 부속 워런트의 현금 또는 무현금 행사로 발행 가능한 928,582주(행사가격 $2.70, 18개월 기간)에서 유래합니다. 2025년 7월 23일 종가 $2.38 기준으로 워런트 행사가격은 시장가보다 약 13% 높으며, 채권 전환 가격은 시장가보다 130% 이상 높습니다. 완전 전환/행사 시 신규 주식은 현재 191만 4천주의 유통 주식 수를 약 74% 확대하여 상당한 매도 압력을 초래할 수 있습니다.

회사는 2차 판매로부터 수익을 받지 않습니다; 모든 워런트를 현금으로 완전히 행사할 경우 약 $250만의 자금을 조달할 수 있으며, 이는 운전자본으로 사용될 예정입니다. 이번 제출은 최근 몇 차례의 자금 조달(3월 전환사채 및 5월 등록 직접 공모)에 이어 이루어졌으며, FDA 승인된 Mytesi를 포함한 크로펠레머 주도 하에 여러 2/3상 임상 프로그램과 희귀의약품 지정이 진행 중인 위장관(GI) 중심의 활발한 신약 파이프라인과 2024년 10월 미국에서 구강 점막염 치료제 Gelclair 출시와 함께 진행되고 있습니다. 파이프라인의 폭넓은 선택권이 있지만, 단기 투자자들은 희석 위험과 매도 주주들의 주식 매도로 인한 가격 압력 가능성을 워런트 행사로 인한 소규모 자금 조달과 비교하여 신중히 고려해야 합니다.

Jaguar Health (JAGX) a déposé un formulaire S-3 pour enregistrer jusqu'à 1 409 732 actions ordinaires en revente par des investisseurs existants. Les actions proviennent de (i) 481 150 actions sous-jacentes à des billets convertibles de remplacement à 6 % émis le 24 juin 2025 (prix de conversion $5,535–$5,555, échéance 30 janvier 2026) et (ii) 928 582 actions pouvant être émises lors de l'exercice en numéraire ou sans numéraire des bons de souscription associés (prix d'exercice $2,70, durée de 18 mois). À la clôture du 23 juillet 2025 à $2,38, les prix d'exercice des bons sont environ 13 % au-dessus du marché tandis que le prix de conversion des billets est supérieur de plus de 130 % au marché. En cas de conversion/exercice complet, les nouvelles actions augmenteraient le flottant actuel de 1,914 million d'actions d'environ 74 %, créant un important surplomb.

La société ne recevra pas de produit des ventes secondaires ; seul un exercice intégral en numéraire de tous les bons pourrait lever environ 2,5 millions de dollars, destinés au fonds de roulement. Ce dépôt fait suite à plusieurs financements récents (billets convertibles de mars et offre directe enregistrée de mai) et intervient parallèlement à un pipeline actif de médicaments axés sur le système gastro-intestinal, mené par le crofelemer (Mytesi approuvé par la FDA, plusieurs programmes de phases 2/3, désignations orphelines) et au lancement prévu en octobre 2024 aux États-Unis de Gelclair pour la mucite buccale. Bien que l'étendue du pipeline offre des options, les investisseurs à court terme doivent peser le risque de dilution et la pression potentielle sur le prix liée aux actionnaires vendeurs par rapport à la modeste injection de capital possible via l'exercice des bons.

Jaguar Health (JAGX) hat ein Formular S-3 eingereicht, um bis zu 1.409.732 Stammaktien zum Wiederverkauf durch bestehende Investoren zu registrieren. Die Aktien stammen aus (i) 481.150 Aktien, die zugrunde liegenden 6 % konvertiblen Ersatzanleihen vom 24. Juni 2025 (Umwandlungspreis $5,535–$5,555, Fälligkeit 30. Januar 2026) und (ii) 928.582 Aktien, die durch Barausübung oder Bar-freie Ausübung der begleitenden Warrants ausgegeben werden können (Ausübungspreis $2,70, Laufzeit 18 Monate). Beim Schlusskurs vom 23. Juli 2025 von $2,38 liegen die Warrant-Ausübungspreise etwa 13 % über dem Markt, während der Umwandlungspreis der Anleihen mehr als 130 % über dem Markt liegt. Bei vollständiger Umwandlung/Ausübung würden die neuen Aktien den aktuellen Streubesitz von 1,914 Millionen Aktien um etwa 74 % erhöhen und damit einen erheblichen Überhang schaffen.

Das Unternehmen erhält keine Erlöse aus Sekundärverkäufen; nur eine vollständige Barausübung aller Warrants könnte etwa 2,5 Millionen US-Dollar einbringen, die für das Betriebskapital vorgesehen sind. Die Einreichung folgt mehreren jüngsten Finanzierungen (März konvertible Anleihen und Mai registriertes Direktangebot) und erfolgt parallel zu einer aktiven, auf den Magen-Darm-Trakt fokussierten Medikamentenpipeline, angeführt von Crofelemer (FDA-zugelassenes Mytesi, mehrere Phase-2/3-Programme, Orphan-Designationen) sowie der Markteinführung von Gelclair gegen orale Mukositis in den USA im Oktober 2024. Obwohl die Breite der Pipeline Optionen bietet, müssen kurzfristige Investoren das Verwässerungsrisiko und den möglichen Preisdruck durch verkaufende Aktionäre gegen den bescheidenen Kapitalzufluss aus der Ausübung der Warrants abwägen.

0000730708false00007307082025-07-242025-07-24


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 24, 2025

SEACOAST BANKING CORPORATION OF FLORIDA
(Exact Name of Registrant as Specified in Charter)
Florida000-1366059-2260678
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
815 COLORADO AVENUE,STUARTFL 34994
(Address of Principal Executive Offices) (Zip Code)


Registrant’s telephone number, including area code (772) 287-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.10 par valueSBCFNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  





SEACOAST BANKING CORPORATION OF FLORIDA




Item 2.02    Results of Operations and Financial Condition

On July 24, 2025, Seacoast Banking Corporation of Florida ("Seacoast or the "Company") announced its financial results for the quarter ended June 30, 2025. A copy of the press release announcing Seacoast’s results for the quarter ended June 30, 2025, is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01    Regulation FD Disclosure

On July 25, 2025, Seacoast will hold an investor conference call to discuss its financial results for the quarter ended June 30, 2025. Attached as Exhibit 99.2 are charts containing information used in the conference call and incorporated herein by reference, which are also available on the Company's website at www.seacoastbanking.com. All information included in the charts is presented as of June 30, 2025, and the Company does not assume any obligation to correct or update said information in the future.

The information in Items 2.02 and 7.01, as well as Exhibits 99.1 and 99.2 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

Item 9.01    Financial Statements and Exhibits

(d) Exhibits
Exhibit No.Description
99.1
Press Release dated July 24, 2025, with respect to Seacoast's financial results for the quarter ended June 30, 2025
99.2
Data on website containing information used in the conference call to be held on July 25, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

Exhibits 99.1 and 99.2 referenced herein, contain “forward-looking statements” within the meaning, and protections, of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements about future financial and operating results, cost savings, enhanced revenues, economic and seasonal conditions in the Company’s markets, and improvements to reported earnings that may be realized from cost controls, tax law changes, new initiatives and for integration of banks that the Company has acquired or expects to acquire, as well as statements with respect to Seacoast's objectives, strategic plans, expectations and intentions and other statements that are not historical facts. Actual results may differ from those set forth in the forward-looking statements.

Forward-looking statements include statements with respect to the Company’s beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates and intentions about future performance and involve known and unknown risks, uncertainties and other factors, which may be beyond the Company’s control, and which may cause the actual results, performance or achievements of Seacoast Banking Corporation of Florida or its wholly-owned banking subsidiary, Seacoast National Bank, to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. You should not expect the Company to update any forward-looking statements.






SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEACOAST BANKING CORPORATION OF FLORIDA

Dated: July 24, 2025/s/ Tracey L. Dexter
 Tracey L. Dexter
 Chief Financial Officer


FAQ

How many Jaguar Health (JAGX) shares are being registered on this Form S-3?

Up to 1,409,732 common shares: 481,150 from convertible notes and 928,582 from warrants.

Will Jaguar Health receive proceeds from this resale registration?

Jaguar receives no proceeds from stockholder sales; it only gains cash if warrants are exercised for $2.70 per share.

What is the potential dilution impact of the newly registered shares?

If all securities convert/exercise, the share count could rise by about 74 % versus the 1.914 M shares outstanding on 21 Jul 2025.

When do the 6 % Replacement Notes mature and at what conversion price?

Notes mature 30 Jan 2026 and convert at $5.535 (non-insiders) or $5.555 (insiders) per share.

What are the warrant terms?

Warrants are exercisable immediately at $2.70 and expire 18 months after issuance or upon a fundamental or liquidation event.

How will any warrant-exercise proceeds be used?

Management plans to apply net cash proceeds, if any, to working capital and general corporate purposes.

What is Jaguar Health’s current Nasdaq ticker and recent share price?

Ticker is JAGX; the last reported price on 23 Jul 2025 was $2.38 per share.
Seacoast Bkg Corp Fla

NASDAQ:SBCF

SBCF Rankings

SBCF Latest News

SBCF Latest SEC Filings

SBCF Stock Data

2.49B
84.37M
1.44%
86.78%
1.83%
Banks - Regional
State Commercial Banks
Link
United States
STUART